Equities analysts expect ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) to report earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Zero analysts have made estimates for ESSA Pharma’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.18). ESSA Pharma reported earnings of ($0.17) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 35.3%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, December 21st.
On average, analysts expect that ESSA Pharma will report full-year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.89). For the next fiscal year, analysts forecast that the company will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.53) to ($0.71). Zacks’ EPS calculations are an average based on a survey of research analysts that cover ESSA Pharma.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its earnings results on Sunday, August 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.05.
In related news, major shareholder Growth N. V. Biotech purchased 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 18th. The stock was bought at an average price of $8.88 per share, for a total transaction of $2,220,000.00. Following the completion of the transaction, the insider now owns 5,015,814 shares in the company, valued at approximately $44,540,428.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.00% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in EPIX. RTW Investments LP grew its position in ESSA Pharma by 976.5% in the second quarter. RTW Investments LP now owns 3,053,919 shares of the company’s stock worth $87,250,000 after acquiring an additional 2,770,227 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of ESSA Pharma by 197.8% during the first quarter. Janus Henderson Group PLC now owns 1,516,102 shares of the company’s stock valued at $44,032,000 after buying an additional 1,007,007 shares during the period. Boxer Capital LLC purchased a new position in shares of ESSA Pharma during the first quarter valued at approximately $19,957,000. Bellevue Group AG boosted its position in shares of ESSA Pharma by 34.7% during the second quarter. Bellevue Group AG now owns 2,459,814 shares of the company’s stock valued at $70,277,000 after buying an additional 634,000 shares during the period. Finally, Rock Springs Capital Management LP purchased a new position in shares of ESSA Pharma during the first quarter valued at approximately $14,613,000. Institutional investors own 84.44% of the company’s stock.
Shares of EPIX stock traded down $0.03 during trading hours on Monday, hitting $8.44. The stock had a trading volume of 601 shares, compared to its average volume of 389,858. ESSA Pharma has a one year low of $5.40 and a one year high of $36.00. The stock’s 50-day moving average price is $9.85 and its two-hundred day moving average price is $21.75. The stock has a market capitalization of $341.45 million, a price-to-earnings ratio of -9.01 and a beta of 1.56.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.
Further Reading: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.